337 related articles for article (PubMed ID: 28465778)
21. Undertreatment, treatment trends, and treatment dissatisfaction among patients with psoriasis and psoriatic arthritis in the United States: findings from the National Psoriasis Foundation surveys, 2003-2011.
Armstrong AW; Robertson AD; Wu J; Schupp C; Lebwohl MG
JAMA Dermatol; 2013 Oct; 149(10):1180-5. PubMed ID: 23945732
[TBL] [Abstract][Full Text] [Related]
22. Integrating biologic agents into management of moderate-to-severe psoriasis: a consensus of the Canadian Psoriasis Expert Panel. February 27, 2004.
Guenther L; Langley RG; Shear NH; Bissonnette R; Ho V; Lynde C; Murray E; Papp K; Poulin Y; Zip C
J Cutan Med Surg; 2004; 8(5):321-37. PubMed ID: 15868311
[TBL] [Abstract][Full Text] [Related]
23. US Perspectives in the Management of Psoriasis and Psoriatic Arthritis: Patient and Physician Results from the Population-Based Multinational Assessment of Psoriasis and Psoriatic Arthritis (MAPP) Survey.
Lebwohl MG; Kavanaugh A; Armstrong AW; Van Voorhees AS
Am J Clin Dermatol; 2016 Feb; 17(1):87-97. PubMed ID: 26718712
[TBL] [Abstract][Full Text] [Related]
24. Psoriasis.
Weigle N; McBane S
Am Fam Physician; 2013 May; 87(9):626-33. PubMed ID: 23668525
[TBL] [Abstract][Full Text] [Related]
25. Paradoxical effects of cost reduction measures in managed care systems for treatment of severe psoriasis.
Yentzer BA; Yelverton CB; Simpson GL; Simpson JF; Hwang W; Balkrishnan R; Feldman SR
Dermatol Online J; 2009 Apr; 15(4):1. PubMed ID: 19450394
[TBL] [Abstract][Full Text] [Related]
26. Economic burden of comorbidities in psoriasis patients in the United States: results from a retrospective U.S. database.
Feldman SR; Tian H; Gilloteau I; Mollon P; Shu M
BMC Health Serv Res; 2017 May; 17(1):337. PubMed ID: 28482887
[TBL] [Abstract][Full Text] [Related]
27. Psoriasis: Which therapy for which patient: Psoriasis comorbidities and preferred systemic agents.
Kaushik SB; Lebwohl MG
J Am Acad Dermatol; 2019 Jan; 80(1):27-40. PubMed ID: 30017705
[TBL] [Abstract][Full Text] [Related]
28. Repaglinide : a pharmacoeconomic review of its use in type 2 diabetes mellitus.
Plosker GL; Figgitt DP
Pharmacoeconomics; 2004; 22(6):389-411. PubMed ID: 15099124
[TBL] [Abstract][Full Text] [Related]
29. Reducing patient copayment levels for topical and systemic treatments in plaque psoriasis as a case for evidence-based, sustainable pharmaceutical policy change in Greece.
Souliotis K; Golna C; Kani C; Litsa P
J Med Econ; 2016 Nov; 19(11):1021-1026. PubMed ID: 27207488
[TBL] [Abstract][Full Text] [Related]
30. Current challenges and emerging drug delivery strategies for the treatment of psoriasis.
Hoffman MB; Hill D; Feldman SR
Expert Opin Drug Deliv; 2016 Oct; 13(10):1461-73. PubMed ID: 27164301
[TBL] [Abstract][Full Text] [Related]
31. [Narrow-band UVB therapy in psoriasis vulgaris: good practice guideline and recommendations of the French Society of Photodermatology].
Beani JC; Jeanmougin M
Ann Dermatol Venereol; 2010 Jan; 137(1):21-31. PubMed ID: 20110064
[TBL] [Abstract][Full Text] [Related]
32. Economic burden of moderate to severe plaque psoriasis in Canada.
Levy AR; Davie AM; Brazier NC; Jivraj F; Albrecht LE; Gratton D; Lynde CW
Int J Dermatol; 2012 Dec; 51(12):1432-40. PubMed ID: 23171010
[TBL] [Abstract][Full Text] [Related]
33. Asian consensus on assessment and management of mild to moderate plaque psoriasis with topical therapy.
Imafuku S; Zheng M; Tada Y; Zhang X; Theng C; Thevarajah S; Zhao Y; Song HJ
J Dermatol; 2018 Jul; 45(7):805-811. PubMed ID: 29740870
[TBL] [Abstract][Full Text] [Related]
34. Review of an established UK home phototherapy service 1998-2011: improving access to a cost-effective treatment for chronic skin disease.
Cameron H; Yule S; Dawe RS; Ibbotson SH; Moseley H; Ferguson J
Public Health; 2014 Apr; 128(4):317-24. PubMed ID: 24726005
[TBL] [Abstract][Full Text] [Related]
35. Quality of life and cost of illness in patients with psoriasis in Malaysia: a multicenter study.
Tang MM; Chang CC; Chan LC; Heng A
Int J Dermatol; 2013 Mar; 52(3):314-22. PubMed ID: 23414155
[TBL] [Abstract][Full Text] [Related]
36. Patients' Perspectives and Experience of Psoriasis and Psoriatic Arthritis: A Systematic Review and Thematic Synthesis of Qualitative Studies.
Sumpton D; Kelly A; Tunnicliffe DJ; Craig JC; Hassett G; Chessman D; Tong A
Arthritis Care Res (Hoboken); 2020 May; 72(5):711-722. PubMed ID: 30927508
[TBL] [Abstract][Full Text] [Related]
37. A pharmacoeconomic analysis of topical therapies for patients with mild-to-moderate stable plaque psoriasis: a US study.
Marchetti A; LaPensee K; An P
Clin Ther; 1998; 20(4):851-69. PubMed ID: 9737842
[TBL] [Abstract][Full Text] [Related]
38. Cost-effectiveness of the two-compound formulation calcipotriol and betamethasone dipropionate compared with commonly used topical treatments in the management of moderately severe plaque psoriasis in Scotland.
Bottomley JM; Auland ME; Morais J; Boyd G; Douglas WS
Curr Med Res Opin; 2007 Aug; 23(8):1887-901. PubMed ID: 17610804
[TBL] [Abstract][Full Text] [Related]
39.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
40.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
